Activation of PPARβ/δ protects cardiac myocytes from oxidative stress-induced apoptosis by suppressing generation of reactive oxygen/nitrogen species and expression of matrix metalloproteinases

Pharmacological Research

Volumn 95-96, Issue , 2015, Pages 102-110

  Barlaka, Eleftheria ^a   Görbe, Anikó ^b,d   Gáspár, Renáta ^b   Pálóczi, János ^b   Ferdinandy, Péter ^c,d   Lazou, Antigone ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF SZEGED   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d PHARMAHUNGARY GROUP   (Hungary)

Author keywords

Apoptosis; Bcl 2; Cardiac myocytes Oxidative stress; Caspase 3; Matrix metalloproteinases; PPAR

Indexed keywords

CASPASE 3; GELATINASE A; GELATINASE B; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN BAX; PROTEIN BCL 2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; 3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; SULFONE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEART MUSCLE CELL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; HYDROGEN PEROXIDE; MALE; MATRIX METALLOPROTEINASES; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PPAR DELTA; PPAR-BETA; RATS, WISTAR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SULFONES; THIAZOLES; THIOPHENES;

EID: 84927155494     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.03.008     Document Type: Article

References (50)

1. C. Ceconi, A. Boraso, A. Cargnoni, and R. Ferrari Oxidative stress in cardiovascular disease: myth or fact? Arch. Biochem. Biophys. 420 2 2003 217 221 10.1016/j.abb.2003.06.002
2. E. Takimoto, and D.A. Kass Role of oxidative stress in cardiac hypertrophy and remodeling Hypertension 49 2 2007 241 248 10.1161/01.HYP.0000254415.31362.a7
3. R.S. Whelan, V. Kaplinskiy, and R.N. Kitsis Cell death in the pathogenesis of heart disease: mechanisms and significance Annu. Rev. Physiol. 72 2010 19 44 10.1146/annurev.physiol.010908.163111
4. A. Clerk, S.M. Cole, T.E. Cullingford, J.G. Harrison, and M. Jormakka Regulation of cardiac myocyte cell death Pharmacol. Ther. 97 3 2003 223 261 10.1016/S0163-7258(02)00339-X
5. A.B. Gustafsson, and R.A. Gottlieb Bcl-2 family members and apoptosis, taken to heart Am. J. Physiol. Cell Physiol. 292 1 2007 C45 C51 10.1152/ajpcell.00229.2006
6. S.N. Willis, and J.M. Adams Life in the balance: how BH3-only proteins induce apoptosis Curr. Opin. Cell Biol. 17 6 2005 617 625 10.1016/j.ceb.2005.10.001
7. A. Page-McCaw, A.J. Ewald, and Z. Werb Matrix metalloproteinases and the regulation of tissue remodelling Nat. Rev. Mol. Cell Biol. 8 3 2007 221 233 10.1038/nrm2125
8. D.A. Siwik, and W.S. Colucci Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium Heart Fail. Rev. 9 1 2004 43 51
9. J. Shen, D. O'Brien, and Y. Xu Matrix metalloproteinase-2 contributes to tumor necrosis factor alpha induced apoptosis in cultured rat cardiac myocytes Biochem. Biophys. Res. Commun. 347 4 2006 1011 1020 10.1016/j.bbrc.2006.07.002
10. G. Dormán, S. Cseh, I. Hajdú, L. Barna, and D. Kónya Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility Drugs 70 May (8) 2010 949 964 10.2165/11318390-000000000-00000
11. Q. Yang, and Y. Li Roles of PPARs on regulating myocardial energy and lipid homeostasis J. Mol. Med. (Berl.) 85 7 2007 697 706 10.1007/s00109-007-0170-9
12. G.D. Girnun, F.E. Domann, S.A. Moore, and M.E. Robbins Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter Mol. Endocrinol. 16 12 2002 2793 2801 10.1210/me.2002-0020
13. Q. Ding, T. Jin, Z. Wang, and Y. Chen Catalase potentiates retinoic acid-induced THP-1 monocyte differentiation into macrophage through inhibition of peroxisome proliferator-activated receptor gamma J. Leukoc. Biol. 81 6 2007 1568 1576 10.1189/jlb.1106672
14. T. Ravingerova, A. Adameova, S. Carnicka, M. Nemcekova, T. Kelly, J. Matejikova, E. Barlaka, and E.A. Lazou The role of PPAR in myocardial response to ischemia in normal and diseased heart Gen. Physiol. Biophys. 30 4 2011 329 341 10.4149/gpb-2011-04-329
15. C. Lotz, M. Lazariotto, A. Redel, T.M. Smul, and J. Stumpner Activation of peroxisome-proliferator-activated receptors α and γ mediates remote ischemic preconditioning against myocardial infarction in vivo Exp. Biol. Med. 236 1 2011 113 122 10.1258/ebm.2010.010210
16. T. Ravingerová, S. Carnická, M. Nemčeková, V. Ledvényiová, A. Adameová, T. Kelly, E. Barlaka, E. Galatou, V.K. Khandelwal, and A. Lazou PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: involvement of PI3K-Akt Can. J. Physiol. Pharmacol. 90 8 2012 1135 1144 10.1139/y2012-052
17. E. Barlaka, V. Ledvényiová, E. Galatou, M. Ferko, and S. Čarnická Delayed cardioprotective effects of WY-14643 are associated with inhibition of MMP-2 and modulation of Bcl-2 family proteins through PPAR-α activation in rat hearts subjected to global ischaemia-reperfusion Can. J. Physiol. Pharmacol. 91 8 2013 608 616 10.1139/cjpp-2012-0412
18. I. Inoue, S. Goto, T. Matsunaga, T. Nakajima, and T. Awata The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells Metabolism 50 1 2001 3 11 10.1053/meta.2001.19415
19. P.J. Smeets, A. Planavila, G.J. van der Vusse, and M. van Bilsen Peroxisome proliferator-activated receptors and inflammation: take it to heart Acta Physiol. (Oxf.) 191 3 2007 171 188 10.1111/j.1748-1716.2007.01752.x
20. L. Cheng, G. Ding, Q. Qin, Y. Huang, and W. Lewis Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy Nat. Med. 10 11 2004 1245 1250 10.1038/nm1116
21. P. Wang, J. Liu, Y. Li, S. Wu, and J. Luo Peroxisome proliferator-activated receptor {delta} is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart Circ. Res. 106 5 2010 911 919 10.1161/CIRCRESAHA.109.206185
22. M.L. Sznaidman, C.D. Haffner, P.R. Maloney, A. Fivush, and E. Chao Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) - synthesis and biological activity Bioorg. Med. Chem. Lett. 13 9 2003 1517 1521 10.1016/S0960-894X(03)00207-5
23. B.G. Shearer, D.J. Steger, J.M. Way, T.B. Stanley, and D.C. Lobe Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist Mol. Endocrinol. 22 2 2008 523 529 10.1210/me.2007-0190
24. T. Markou, A.A. Dowling, T. Kelly, and A. Lazou Regulation of Bcl-2 phosphorylation in response to oxidative stress in cardiac myocytes Free Radic. Res. 43 9 2009 809 816 10.1080/10715760903071649
25. D. Cieslak, and A. Lazou Regulation of BAD protein by PKA, PKCdelta and phosphatases in adult rat cardiac myocytes subjected to oxidative stress Mol. Cells 24 2 2007 224 231
26. T. Markou, E. Barlaka, M. Bartucci, and A. Lazou Signal transduction pathways through cytoprotective, apoptotic and hypertrophic stimuli: a comparative study in adult cardiac myocytes Cell Biochem. Funct. 29 6 2011 442 451 10.1002/cbf.1770
27. M.A. O'Brien, R.A. Moravec, and T.L. Riss Poly (ADP-ribose) polymerase cleavage monitored in situ in apoptotic cells Biotechniques 30 4 2001 886 891
28. M. Pesant, S. Sueur, P. Dutartre, M. Tallandier, and P.A. Grimaldi Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis Cardiovasc. Res. 69 2 2006 440 449 10.1016/j.cardiores.2005.10.019
29. P. Liu, M. Sun, and S. Sader Matrix metalloproteinases in cardiovascular disease Can. J. Cardiol. 22 Suppl. B 2006 25B 30B
30. A.L. Jacob-Ferreira, and R. Schulz Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: consequences and therapeutic strategies in the heart Arch. Biochem. Biophys. 540 1-2 2013 82 93 10.1016/j.abb.2013.09.019
31. T.L. Yue, S.S. Nerurkar, W. Bao, B.M. Jucker, and L. Sarov-Blat In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats J. Pharmacol. Exp. Ther. 325 2 2008 466 474 10.1124/jpet.107.135327
32. A. Kapoor, M. Collino, S. Castiglia, R. Fantozzi, and C. Thiemermann Activation of peroxisome proliferator-activated receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat Shock 34 2 2010 117 124 10.1097/SHK.0b013e3181cd86d6
33. F. Liang, F. Wang, S. Zhang, and D.G. Gardner Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes Endocrinology 144 9 2003 4187 4194 10.1210/en.2002-0217
34. A. Planavila, J.C. Laguna, and M. Vázquez-Carrera Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation Biochim. Biophys. Acta 1687 1-3 2005 76 83 10.1016/j.bbalip.2004.11.004
35. L. Sheng, P. Ye, Y.X. Liu, C.G. Han, and Z.Y. Zhang Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro Clin. Exp. Hypertens. 30 2 2008 109 119 10.1080/10641960801945840
36. J. Liu, P. Wang, J. Luo, Y. Huang, and L. He Peroxisome proliferator-activated receptor β/δ activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition Hypertension 57 2 2011 223 230 10.1161/HYPERTENSIONAHA.110.164590
37. H. Lee, S.A. Ham, M.Y. Kim, J.H. Kim, and K.S. Paek Activation of PPARδ counteracts angiotensin II-induced ROS generation by inhibiting rac1 translocation in vascular smooth muscle cells Free Radic. Res. 46 7 2012 912 919 10.3109/10715762.2012.687448
38. E. Galatou, T. Kelly, and A. Lazou The PPARβ/δ agonist GW0742 modulates signaling pathways associated with cardiac myocyte growth via a non-genomic redox mechanism Mol. Cell. Biochem. 395 1-2 2014 145 154 10.1007/s11010-014-2120-5
39. K. Imahashi, M.D. Schneider, C. Steenbergen, and E. Murphy Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury Circ. Res. 95 7 2004 734 741 10.1161/01.RES.0000143898.67182.4c
40. J.T. Peterson The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors Cardiovasc. Res. 69 3 2006 677 687 10.1016/j.cardiores.2005.11.032
41. M. Dobaczewski, C. Gonzalez-Quesada, and N.G. Frangogiannis The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction J. Mol. Cell. Cardiol. 48 3 2010 504 511 10.1016/j.yjmcc.2009.07.015
42. R. Schulz Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches Annu. Rev. Pharmacol. Toxicol. 47 2007 211 242 10.1146/annurev.pharmtox.47.120505.105230
43. W. Wang, C.J. Schulze, W.L. Suarez-Pinzon, J.R. Dyck, and G. Sawicki Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury Circulation 106 12 2002 1543 1549 10.1161/01.CIR.0000028818.33488.7B
44. G. Sawicki, H. Leon, J. Sawicka, M. Sariahmetoglu, and C.J. Schulze Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2 Circulation 112 4 2005 544 552 10.1161/CIRCULATIONAHA.104.531616
45. J.A. Kwan, C.J. Schulze, W. Wang, H. Leon, and M. Sariahmetoglu Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro FASEB J. 18 6 2004 690 692 10.1096/fj.02-1202fje
46. A. DeCoux, M.L. Lindsey, F. Villarreal, R.A. Garcia, and R. Schulz Myocardial matrix metalloproteinase-2: inside out and upside down J. Mol. Cell. Cardiol. 77 2014 64 72 10.1016/j.yjmcc.2014.09.016
47. C.Q. Gao, G. Sawicki, W.L. Suarez-Pinzon, T. Csont, and M. Wozniak Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction Cardiovasc. Res. 57 2 2003 426 433 10.1016/S0008-6363(02)00719-8
48. S. Philip, A. Bulbule, and G.C. Kundu Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion Glycoconj. J. 21 8-9 2004 429 441
49. C.S. Lee, Y.W. Kwon, H.M. Yang, S.H. Kim, and T.Y. Kim New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9 Arterioscler. Thromb. Vasc. Biol. 29 4 2009 472 479 10.1161/ATVBAHA.108.176230
50. H.J. Kim, M.Y. Kim, J.S. Hwang, H.J. Kim, and J.H. Lee PPARdelta inhibits IL-1beta-stimulated proliferation and migration of vascular smooth muscle cells via up-regulation of IL-1Ra Cell. Mol. Life Sci. 67 12 2010 2119 2130 10.1007/s00018-010-0328-4